Targretin

RSS

bexarotene

Authorised
This medicine is authorised for use in the European Union.

Overview

Targretin is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. Targretin is used in patients who have an advanced disease and have had at least one other treatment.

This EPAR was last updated on 26/01/2022

Authorisation details

Product details
Name
Targretin
Agency product number
EMEA/H/C/000326
Active substance
bexarotene
International non-proprietary name (INN) or common name
bexarotene
Therapeutic area (MeSH)
Lymphoma, T-Cell, Cutaneous
Anatomical therapeutic chemical (ATC) code
L01XF03
Publication details
Marketing-authorisation holder
Eisai GmbH
Revision
23
Date of issue of marketing authorisation valid throughout the European Union
29/03/2001
Contact address

Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany

Product information

21/06/2021 Targretin - EMEA/H/C/000326 - IA/0060

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating